Partnerships are an important component of our business plan. We have developed valuable relationships with world-class biotechnology and biopharmaceutical companies and have established research collaborations with distinguished academic investigators. Contact us today to learn more about our clinical programs or to find out how we can help you succeed with your antibody selection.
Collaboration Partner: Merck KGaA, Darmstadt, Germany
Clinical evaluation of the safety and effectiveness of VX15/2503 in combination with avelumab (anti-PD-L1) in the treatment of advanced non-Small Cell Lung Cancer (NSCLC).
ClinicalTrials.gov Identifier: NCT03268057
Collaboration Partner: Catalent Pharma Solutions
Research collaboration with Catalent for the creation of novel anti-cancer agents.
Collaboration Partner: Surface Oncology, Inc.
Research collaboration with Surface Oncology for discovery and selection of monoclonal antibodies to oncology targets.
Collaboration Partner: Biocon Limited
Co-development collaboration in which Biocon and Vaccinex jointly discover, develop and commercialize therapeutic antibody products.
Collaboration Partner: NIH-NCI
Preclinical evaluation of VX15 in Head and Neck Cancer.
Collaboration Partner: NCI- Children’s Oncology Group
Clinical evaluation of the safety and effectiveness of VX15/2503 in the treatment of pediatric osteosarcoma.
ClinicalTrials.gov Identifier: NCT03320330
Collaboration Partner: Emory University
Clinical Evaluation of VX15 in combination with immune checkpoint inhibitors in neoadjuvant biomarker trials in oncology.
ClinicalTrials.gov Identifier: NCT03373188 (Resectable Pancreatic and Colorectal Cancer)
ClinicalTrials.gov Identifier: NCT03690986 (Resectable Head and Neck Cancer)
ClinicalTrials.gov Identifier: NCT03769155 (Resectable Melanoma)
Collaboration Partner: UCLA
Clinical Evaluation of VX15 in combination with immune checkpoint inhibitors in melanoma.
ClinicalTrials.gov Identifier: NCT03425461